Entera Bio Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Entera Bio Ltd., a foreign private issuer, covers the month of August 2021. The report, dated August 2, 2021, consists solely of a press release attached as Exhibit 99.1. The registrant is headquartered in Jerusalem, Israel, and files annual reports under Form 20-F.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document serves as a vehicle to incorporate a press release by reference and does not contain a financial statement or quantitative financial data.
Material Changes
The filing text does not provide a clear value regarding material changes versus the prior comparable period. The content is limited to the incorporation of a press release without specific comparative financial or operational data in the provided text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. While the filing incorporates a press release, the specific content of that release is not included in the provided text.
Key Facts for Investor Verification
- The filing is a procedural Form 6-K incorporating a press release dated August 2, 2021, rather than a standalone financial report.
- No financial metrics (revenue, cash, debt) are disclosed within the text of this specific filing.
- Investors must review Exhibit 99.1 (the press release) separately to understand the specific corporate event or announcement triggering this filing.
- The registrant is authorized by Spiros Jamas, Sc.D., Chief Executive Officer and Director.